Praxis Precision Medicines, Inc. (PRAX) surged 5.88% in pre-market trading after the company reported second-quarter financial results that exceeded analyst expectations and provided a positive update on its late-stage pipeline.

The biopharmaceutical company posted a loss of $2.87 per share for the second quarter, beating the consensus estimate of a $3.65 loss by 21.37%. The narrower-than-expected loss was driven by disciplined spending and increasing efficiency in its clinical programs.

Investor sentiment was further buoyed by encouraging regulatory developments. Praxis announced that mid-cycle meetings with the FDA for both ulixacaltamide (for essential tremor) and relutrigine (for SCN2A and SCN8A developmental and epileptic encephalopathies) were completed successfully, with no major safety or efficacy concerns identified. The FDA also confirmed that no advisory committee meetings are planned for either candidate, and Bioresearch Monitoring inspections concluded with no Form 483 observations. Additionally, the company received its third Breakthrough Therapy Designation for elsunersen, reinforcing its leadership in CNS precision medicine. With a cash runway into 2028 and accelerating commercial preparations, the market reacted positively to the company's progress toward potential near-term product approvals.